Systematic Review and Network Meta-Analysis of Lorlatinib with Comparison to Other Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (tkis) As First-Line Treatment for ALK-positive Advanced Non-Smallcell Lung Cancer (NSCLC).
Lung Cancer（2024）
Key words
Network meta-analysis,NSCLC,ALK-positive,First-line,Lorlatinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined